Faron announces extension to key patent family with new US patent granted
Faron Pharmaceuticals has announced that the United States Patent and Trademark Office has granted a new US Patent for treatment of Clever-1 positive cancers with bexmarilimab and related structures that would bind to Clever-1 molecule for the wanted re-programming effect.
August 18, 2025
The patent is granted based on divisional application from the original “composition of matter” patent covering the structure of bexmarilimab. The original application included the composition matter claims as well as the treatment method. The new granted patent covers treating cancers that have Clever-1 positive cells in the tumor microenvironment with such structures. A patent covering the composition of matter of bexmarilimab was already granted four years ago with patent life up to 2037 without extensions.
Based on the long application process of the division application, the term of the newly granted patent has been adjusted beyond the standard twenty years lasting until February 2040.
The Jalkanens: A shared thirst for knowledge
For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.
“This significantly extends our key patent life on the use of bexmarilimab for the treatment of relevant cancers, that have Clever-1 positive tumour associated macrophages or blasts cells, such as in AML & MDS,” says Faron’s CEO Juho Jalkanen.
”The patent family around targeting Clever-1 in cancer is strong and we believe bexmarilimab will enjoy a long patent life once marketed, given how far it is in clinical development already”, continues Jalkanen.
Published: August 18, 2025
